



Brand Name : PINNACLE AMLODIPINE 5		2018
Generic Name : AMLODIPINE BESYLATE TABLETS USP 5 MG		
Module 1 : Administrative Information		Confidential
1.3	: Product information	
1.3.1	: Summary of Product Characteristics (SmPC)	

1.3.1 Summary of Product Characteristics (SmPC)

1- Name of the Medicinal Product:

1.1 Product Name

-Generic Name or International Non-Proprietary Name (INN)

Amlodipine Besylate Tablets USP 5 mg

-Brand Name

PINNACLE AMLODIPINE 5

1.2 Dosage Strength

Each uncoated tablet contains:

Amlodipine Besylate USP

Eq. to Amlodipine.....5 mg

Excipients.....q.s.

1.3 Dosage Form

Oral tablets

2- Quality and Quantitative Composition:

2.1 Qualitative Declaration

Each uncoated tablet contains:

Amlodipine Besylate USP

Eq. to Amlodipine.....5 mg

Excipients.....q.s.

RA EXECUTIVE


Prepared By

Q.A.MANAGER


Approved By



2.2 Quantitative Declaration

Composition:

Batch Size - 1,00,000 Tablets.

Sr. No	Ingredients	Labeled Claim	Specification	mg/Tab	Qty/Batch 1 lac in Kg	Function
DRY MIXING						
1	Amlodipine Besylate Eq. to Amlodipine	5 mg	USP	6.92	0.69	Active
2	Maize Starch	---	BP	185.68	18.56	Diluent
3	Dibasic Calcium Phosphate	---	BP	90.00	9.00	Diluent
4	Microcrystalline Cellulose plain	---	BP	56.00	5.60	Diluent
GRANULATION						
5	Methyl Paraben	---	BP	1.00	0.10	Preservative
6	Propyl Paraben	---	BP	0.40	0.04	Preservative
7	Maize Starch	---	BP	12.00	1.20	Binder
8	Purified water*	---	BP	q.s	q.s	Binding solvent
LUBRICATON						
9	Sodium Starch Glycolate	---	BP	7.00	0.70	Disintegrant
10	Magnesium Stearate	---	BP	5.00	0.50	Lubricant
11	Purified Talc	---	BP	6.00	0.60	Lubricant
AVG. WT. OF UNCOATED TABLETS =				370 mg	(Limit: 370 mg \pm 5.0%)	

NOTE: Active material is to be calculated on Assay / Potency basis.

USP = United States Pharmacopoeia,

BP = British Pharmacopoeia.

* Does not appear in the finished Product.

RA EXECUTIVE


Prepared By

43 of 71

Q.A.MANAGER


Approved By



3- **Pharmaceutical Form:**

White Coloured Round Shaped Flat Uncoated Tablets having break line on one side of the tablet.

4- **Clinical Particulars:**

4.1 **Therapeutic indications**

Essential hypertension.

Chronic stable and vasospastic (Prinzmetal's) angina pectoris.

4.2 **Posology and method of administration**

Posology

Adults

For treatment of both hypertension and angina pectoris the usual initial dose is 5 mg once daily. If the desired therapeutic effect cannot be achieved within 2-4 weeks this dose may be increased to a maximum dose of 10 mg daily (as single dose) depending on the individual patient's response.

In hypertensive patients, amlodipine has been used in combination with a thiazide diuretic, alpha-blocker, beta-blocker, or an angiotensin converting enzyme inhibitor. For angina, amlodipine may be used as monotherapy or in combination with other antianginal medicinal products in patients with angina that is refractory to nitrates and/or to adequate doses of beta blockers.

No dose adjustment of amlodipine is required upon concomitant administration of thiazide diuretics, beta-blockers, and angiotensin-converting enzyme inhibitors.

Paediatric population

Children with hypertension from 6 years to 17 years of age.

The recommended antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients.

Children under 6 years old

The effect of amlodipine on blood pressure in patients less than 6 years of age is not known.

The 2.5 mg dose cannot be obtained with Amlodipine tablets 5 mg as these tablets are not manufactured to break into two equal halves

Elderly

Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.

RA EXECUTIVE


Prepared By

44 of 71

Q.A.MANAGER


Approved By



Renal impairment

Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dialysable.

Hepatic impairment

Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range. The pharmacokinetics of Amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.

Method of administration

Tablets for oral administration. The tablets should be taken with a glass of water independently from meals.

4.3 **Contraindications**

Amlodipine is contra-indicated in patients with:

- severe hypotension
- shock (including cardiogenic shock)
- haemodynamically unstable heart failure after acute myocardial infarction (during the first 28 days)
- obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis)

4.4 **Special warning and precautions for use**

The safety and efficacy of amlodipine in hypertensive crisis has not been established.

Cardiac failure

Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group, but this was not indicating an aggravation of the heart failure. Calcium channel blockers, including Amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.

Impaired hepatic function

The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.

RA EXECUTIVE


Prepared By

45 of 71

Q.A.MANAGER


Approved By



Elderly patients

In the elderly, increase of the dosage should take place with care.

Renal failure

Amlodipine may be used in such patients at normal doses. Change in Amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialyzable.

Paediatric population

Amlodipine should not be given to children due to insufficient clinical experience.

4.5 Interaction with other medicinal products and other forms of interaction

Effects of other medicinal products on amlodipine

CYP3A4 inhibitors: Concomitant use of Amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.

CYP3A4 inducers: There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.

Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.

Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the coadministration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.

Effects of amlodipine on other medicinal products

The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other antihypertensive agents.

In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or ciclosporin.

RA EXECUTIVE


Prepared By

46 of 71

Q.A.MANAGER


Approved By



Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.

4.6 Fertility, Pregnancy and lactation

Pregnancy

The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses. Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.

Breast-feeding

It is not known whether amlodipine is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.

Fertility

Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility.

4.7 Effects on ability to drive and use machine

Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment..

4.8 Undesirable effects

Summary of safety profile

The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.

The following undesirable effects have been observed and reported during treatment with Amlodipine with the following frequencies:

Very common	$\geq 1/10$
:	
Common:	$\geq 1/100$ to $< 1/10$
Uncommon:	$\geq 1/1000$ to $\leq 1/100$
Rare:	$\geq 1/10\ 000$ to $\leq 1/1000$

RA EXECUTIVE


Prepared By

47 of 71

Q.A.MANAGER


Approved By



Globela Pharma Pvt. Ltd

Very rare: $\leq 1/10\ 000$

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System organ class	Frequency	Adverse reactions
Blood and lymphatic system disorders	Very rare	Leukocytopenia, thrombocytopenia
Immune system disorders	Very rare	Allergic reactions
Metabolism and nutrition disorders	Very rare	Hyperglycaemia
Psychiatric disorders	Uncommon	Insomnia, mood changes (including anxiety), depression
	Rare	Confusion
Nervous system disorders	Common	Somnolence, dizziness, headache (especially at the beginning of the treatment)
	Uncommon	Tremor, dysgeusia, syncope, hypoesthesia, paresthesia
	Very rare	Hypertonia, peripheral neuropathy
Eye disorders	Uncommon	Visual disturbance (including diplopia)
Ear and labyrinth disorders	Uncommon	Tinnitus
Cardiac disorders	Common	Palpitations
	Very rare	Myocardial infarction, arrhythmia (including bradycardia and atrial fibrillation)
Vascular disorders	Common	Flushing
	Uncommon	Hypotension
	Very rare	Vasculitis
Respiratory, thoracic and mediastinal disorders	Uncommon	Dyspnoea, rhinitis
	Very rare	Cough
Gastrointestinal disorders	Common	Abdominal pain, nausea
	Uncommon	Vomiting, dyspepsia, altered bowel habits (including diarrhoea and constipation), dry mouth
	Very rare	Pancreatitis, gastritis, gingival hyperplasia
Hepatobiliary disorders	Very rare	Hepatitis, jaundice, hepatic enzymes increased*
Skin and	Uncommon	Alopecia, purpura, skin discolouration,

RA EXECUTIVE


Prepared By

Q.A.MANAGER


Approved By



subcutaneous tissue disorders		hyperhidrosis, pruritus, rash, exanthema
	Very rare	Angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quinckeoedema, photosensitivity
Musculoskeletal and connective tissue disorders	Common	Ankle swelling
	Uncommon	Arthralgia, myalgia, muscle cramps, back pain
Renal and urinary disorders	Uncommon	Micturition disorder, nocturia, increased urinary frequency
Reproductive system and breast disorders	Uncommon	Impotence, gynecomastia
General disorders and administration site conditions	Common	Oedema, fatigue
	Uncommon	Chest pain, asthenia, pain, malaise
Investigations	Uncommon	Weight increase, weight decrease
Special senses	Uncommon	Tinnitus

Exceptional cases of extra pyramidal syndrome have been reported.

4.9 Overdose and treatment

In humans, experience with intentional overdose is limited.

Symptoms

Available data suggest that large overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.

Management

Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output.

A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10mg has been shown to reduce the absorption rate of amlodipine. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.

RA EXECUTIVE


Prepared By

Q.A.MANAGER


Approved By



5- Pharmacological Properties:

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Calcium channel blockers, selective calcium channel blockers with mainly vascular effects

ATC code: C08CA01

Mechanism of action

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

The mechanism of the antihypertensive action is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but Amlodipine reduces total ischaemic burden by the following two actions:

1. Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.

2. The mechanism of action of Amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilation increases myocardial oxygen delivery in patients with coronary artery spasm (prinzmetals or variant angina).

Clinical efficacy and safety

In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both supine and standing positions throughout the 24 hour interval. Due to slow onset of action, acute hypotension is not a feature of Amlodipine administration.

In patients with angina, once daily administration of amlodipine increases total exercise time, the delay of occurrence of anginal attack and the delay of the occurrence of a 1-mm ST interval. Amlodipine decreases both angina attack frequency and glyceryltrinitrate tablet consumption.

Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.

Coronary artery disease (CAD)

The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-center, randomized, double-blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in

RA EXECUTIVE


Prepared By

50 of 71

Q.A.MANAGER


Approved By



Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.

Cardiac failure

Haemodynamic studies and exercise based clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.

A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure patients receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or a combined risk of mortality and morbidity with heart failure.

In a follow-up, long term, placebo controlled study (PRAISE-2) of Amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, Amlodipine had no effect on total cardiovascular mortality. In this same population Amlodipine was associated with increased reports of pulmonary oedema.

Treatment to prevent heart attack trial (ALLHAT)

A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.”

A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (> 6 months prior to enrolment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C < 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).

The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.

Paediatric population (aged 6 years and older)

In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood

RA EXECUTIVE


Prepared By

51 of 71

Q.A.MANAGER


Approved By



Pressure significantly more than placebo. The difference between the two doses was not statistically significant.

The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood have also not been established.

5.2 Pharmacokinetic Properties

Absorption

After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absorption of amlodipine is not influenced by concomitant food intake. Absolute bioavailability of the unchanged active substance is estimated to be 64-80%. Peak plasma levels are reached 6-12 hours after administration.

Distribution

The volume of distribution is approximately 21 l/kg. The pKa of amlodipine is 8.6. In vitro studies have shown that amlodipine is bound to plasmatic proteins up to 97.5%.

Biotransformation

Amlodipine is extensively metabolized by the liver to inactive metabolites with 10% of the parent compound.

Elimination

The plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. 60% of metabolites are excreted in the urine.

Hepatic impairment

Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.

Elderly

The time to reach peak plasma concentrations is similar in elderly and younger patients. The clearance tends to be decreased with resulting increases in (AUC) and terminal elimination half-life in elderly patients. Increase in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.

Pediatric population

A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either

RA EXECUTIVE


Prepared By

52 of 71

Q.A.MANAGER


Approved By



once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.

5.3 Preclinical safety Data

Reproductive toxicology

Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.

Impairment of fertility

There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m² basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.

Carcinogenesis, mutagenesis

Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m² basis) was close to the maximum tolerated dose for mice but not for rats.

Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.

* Based on patient weight of 50kg.

RA EXECUTIVE


Prepared By

53 of 71

Q.A.MANAGER


Approved By



6- Pharmaceutical Particulars :

6.1 List of Excipients

Maize Starch
Dibasic calcium phosphate
Microcrystalline cellulose
Methyl Paraben
Propyl Paraben
Sodium starch glycollate
Magnesium Stearate
Purified talc

6.2 Incompatibilities

None known

6.3 Shelf life

36 months from the date of manufacture.

6.4 Special precautions for storage

Store in a cool and dry place, protected from light

6.5 Nature and contents of container

10 Tablets packed in one Alu Alu blister. Such 3 Blisters packed in unit printed duplex board carton along with its package insert. Such cartons packed in export worthy shipper.

Note: All pack style may not be marketed.

7- Marketing Authorization Holder:

- Name : GLOBELA PHARMA PVT. LTD.

- Address : Plot No. 357, G.I.D.C.,
Sachin,
Surat – 394 230,
Gujarat,
India.

- Phone : +91– 261–2398058

- Fax : +91– 261–2398058

- E-mail : info@globelapharma.com

RA EXECUTIVE


Prepared By

54 of 71

Q.A.MANAGER


Approved By



Globela Pharma Pvt. Ltd

8- Marketing Authorization Number (s):

-Product license / registration Number (s)

9- Manufacturer Name:

- Name : GLOBELA PHARMA PVT. LTD.

- Address : Plot No. 357, G.I.D.C.,
Sachin,
Surat – 394 230,
Gujarat,
India.

- Phone : +91– 261–2398058

- Fax : +91– 261–2398058

- E-mail : info@globelapharma.com

10- Date of first authorization/renewal of the authorization:

11- Date of revision of the text:

RA EXECUTIVE


Prepared By

55 of 71

Q.A.MANAGER


Approved By